BMA, short for BMA Biomedicals, is a small biotech company located in the Basel area in northern Switzerland. Founded in 1989 by a group of immunologists, biochemists and biologists, its main area of activity is in the development, production and marketing of antibodies. In 2005, BMA was acquired by Chemoforma Inc., a long-time business partner active in the production of immune-supportive feed additives. In 2013, Chemoforma Inc. acquired Peninsula Laboratories International, Inc., a California-based company specialized in anti-peptide antibodies and radioimmunoassays.
BMA's main expertise lies in the application of antibodies in immunohistochemistry and enzyme immunoassays (ELISAs). Production has fully been adapted to culture media without fetal calf serum. This is not only an important contribution to sustainability and animal welfare, but the products contain no contaminating bovine antibodies. They are generally offered for in vitro research use only, but the licensing of appropriate products to companies in the diagnostics field is supported.
BMA operates its own facilities with state-of-the-art analytical and production infrastructure. Our know-how lies in the production and derivatisation of monoclonal and polyclonal antibodies, and their use in immunological techniques. BMA also licenses products from outside organizations. These may be in early development stages and are finally updated for manufacture by the company.
The product range of BMA is customer oriented and includes many products that focus on limited or specialized applications. Some are produced exclusively by BMA, others are routine products with extensive publication records.
BMA's product focus includes the fields of
- inflammation and infectious diseases
- tumor related diseases
- veterinary reagents, in particular antibodies against porcine tissue
BMA sells its products to all countries worldwide. To learn more please refer to the distributors' section in the menu.